RESULTS OF COMBINATION TREATMENT IN REPRODUCTIVE-AGED PATIENTS WITH HYSTEROMYOMA ACCOMPANIED BY MENORRHAGIAS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

What management tactics should be for reproductive-aged patients with hysteromyoma accompanied by menorrhagias also remains relevant at the present time. Objective. To enhance the efficiency of combination treatment in reproductive-aged patients with hysteromyoma accompanied by menorrhagias and anemia. Subjects and methods. The investigation enrolled 55 reproductive-aged women with hysteromyoma accompanied by menorrhagias and anemia. A study group (Group 1) comprised 30 patients who were preoperatively treated with ulipristal acetate in combination with iron-containing drugs for 3 months and then underwent myomectomy. A control group (Group 2) included 25 patients who underwent surgery (myomectomy) with no previous drug therapy. Results. Three months after starting medical therapy, all the patients in Group 1 stopped menstruating completely. The size of myomatous nodules and uterus significantly decreased in Group 1. There was a statistically significant elevation in the level of hemoglobin in 100% of the women in the study group (p <0.01). Laparoscopic myomectomy was performed in both groups. Total intraoperative blood loss and the duration of surgery were found to reduce in Group 1. There was a decreased postoperative length of hospital stay. Conclusion. The use of ulipristal acetate in combination with iron-containing drugs is effective for preoperative preparation for reconstructive plastic intervention in reproductive-aged patients with hysteromyoma accompanied by menorrhagias and anemia.

Full Text

Restricted Access

About the authors

Zarina V. Revazova

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: atias@bk.ru
graduate student Moscow 117997, Ac. Oparina str. 4, Russia

Leila V. Adamyan

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia; Moscow State Medical and Dental University

Email: adamyanleila@gmail.com
member of RAS, Doctor of Medicine, Professor, Deputy Director for Science; Honored Scientist of Russia; main specialist in obstetrics and gynecology of the Ministry of Health of Russia; Head of the Department of Reproductive Medicine and Surgery, Faculty of Postgraduate Education Moscow 117997, Ac. Oparina str. 4, Russia

Andrey V. Kozachenko

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: a_kozachenko@oparina4.ru
MD, leading researcher Moscow 117997, Ac. Oparina str. 4, Russia

References

  1. Адамян Л.В., ред. Миома матки: диагностика, лечение и реабилитация. Клинические рекомендации по ведению больных. М.; 2015
  2. Wallach E.E., Vlahos N.F. Uterine myomas: an overview of development, clinical features, and management. Obstet. Gynecol. 2004; 104(2): 393-406. doi: 10.1097/01.AOG.0000136079.62513.39.
  3. Maruo T., Ohara N., Wang J., Matduo H. Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum. Reprod. Update. 2004; 10(3): 207-20. doi: 10.1093/humupd/dmh019.
  4. Mettler L., Schollmeyer T., Tinelli A., Malvasi A., Alkatout I. Complications of uterine fibroids and their management, surgical management of fibroids, laparoscopy and hysteroscopy versus hysterectomy, haemorrhage, adhesions, and complications. Obstet. Gynecol. Int. 2012; 2012: 791248. doi: 10.1155/2012/791248.
  5. Fonseca-Moutinho J.A., Barbosa L.S., Torres D.G., Nunes S.M. Abnormal uterine bleeding as a presenting symptom is related to multiple uterine leiomyoma: an ultrasound-based study. Int. J. Women’s Health. 2013; 5: 689-94. doi: 10.2147/ IJWH.S50786.
  6. Tsiligianis S.E., Zaitseva M., Coombs P., Shekleton P., Olshansky M., Hickey M. et al. Fibroid-associated heavy menstrual bleeding: correlation between clinical features, Doppler ultrasound assessment of vasculature, and tissue gene expression profiles. Reprod. Sci. 2012; 20(4): 361-70. doi: 10.1177/1933719112459233.
  7. Stewart E.A., Nowak R.A. Leiomyoma-related bleeding: a classic hypothesis updated for the molecular era. Hum. Reprod. Update. 1996; 2(4): 295-306.
  8. Lockwood Ch.J. Mechanisms of normal and abnormal endometrial bleeding. Menopause. 2011; 18(4): 408-11. doi: 10/1097/GME.0b013e31820bf288.
  9. David-Montefiore E., Rouzier R., Chapron C., Darai E. Surgical routes and complications of hysterectomy for benign disorders: a prospective observational study in French university hospitals. Hum. Reprod. 2007; 22(1): 260-5. doi: 10.1093/ humrep/del336.
  10. Islam M.S., Protic O., Giannubilo S.R., Toti P., Tranquilli A.L., Petraglia F. et al. Uterine leiomyoma: available medical treatments and new possible therapeutic options. J. Clin. Endocrinol. Metab. 2013; 98(3): 921-34. doi: 10.1210/ jc.2012-3237.
  11. Adamson G.D. Treatment of uterine fibroids: current findings with gonadotropin-releasing hormone agonists. Am. J. Obstet. Gynecol. 1992; 166(2): 746-51. doi: 10.1016/0002-9378(92)91707-H.
  12. Lethaby A., Vollenhoven B., Sowter M. Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review. BJOG. 2002; 109(10): 1097-108. doi: 10.1111/j.1471-0528.2002.01225.x.
  13. Parker W.H. Etiology, symptomatology, and diagnosis of uterine myomas. Fertil. Steril. 2007; 87(4): 725-36. doi: 10.1016/j.fertnstert.2007.01.093.
  14. Donnez J., Tatarchuk T.F., Bouchard P., Puscasiu L., Zakharenko N.F., Ivanova T. et al.; PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery. N. Engl. J. Med. 2012; 366(5): 409-20. doi: 10.1056/ NEJMoa1103182.
  15. Donnez J., Tomaszewski J., Vazquez F., Bouchard P., Lemieszczuk B., Baro F. et al.; PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N. Engl. J. Med. 2012; 366(5): 421-32. doi: 10.1056/NEJMoa1103180.
  16. Munro M.G., Critchley H.O., Fraser I.S. The FIGO systems for nomenclature and classification of causes of abnormal uterine bleeding in the reproductive years: who needs them? Am. J. Obstet. Gynecol. 2012; 207(4): 259-65. doi: 10.1016/j. ajog.2012.01.046.
  17. Barlow D.H., Lumsden M.A., Fauser B.C., Terrill P., Bestel E. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Hum. Reprod. 2014; 29(3): 480-9. doi: 10.1093/humrep/det467.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies